Sage Therapeutics, Inc. (SAGE)
- Previous Close
13.58 - Open
13.87 - Bid 13.65 x 400
- Ask 13.69 x 200
- Day's Range
13.38 - 13.91 - 52 Week Range
10.92 - 59.99 - Volume
1,461,453 - Avg. Volume
1,050,773 - Market Cap (intraday)
823.892M - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-8.39 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.06
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
www.sagerx.comRecent News: SAGE
Performance Overview: SAGE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SAGE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SAGE
Valuation Measures
Market Cap
823.89M
Enterprise Value
110.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.01
Price/Book (mrq)
1.17
Enterprise Value/Revenue
1.21
Enterprise Value/EBITDA
-0.22
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.98%
Return on Equity (ttm)
-54.72%
Revenue (ttm)
91.06M
Net Income Avi to Common (ttm)
-503.14M
Diluted EPS (ttm)
-8.39
Balance Sheet and Cash Flow
Total Cash (mrq)
717.01M
Total Debt/Equity (mrq)
0.47%
Levered Free Cash Flow (ttm)
-232.9M
Research Analysis: SAGE
Company Insights: SAGE
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: SAGE
Daily – Vickers Top Buyers & Sellers for 11/16/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/10/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/18/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.